文献速递神经肿瘤

分次方案对颅内脑膜瘤无框架直线加速器图像引导立体定向放射外科和放疗后局部控制的影响

Impact of Fractionation Regimen on Local Control Following Frameless Linear Accelerator-Based Image-Guided Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma.
PubMed 文献 · World Neurosurg · 2024-07-26

该回顾性研究纳入543例患者共613个颅内脑膜瘤病灶,比较立体定向放射外科、分次立体定向放射外科和常规分次立体定向放疗三种技术的局部控制。中位随访8.0年,所有病灶5/10/14年局部控制率为97.4%/86.8%/86.8%,三种分次方案间无差异,颅底位置、肿瘤体积≥5 cc和复发疾病与更差局部控制相关。

要点

  • 所有病灶5/10/14年局部控制率为97.4%/86.8%/86.8%。
  • 三种分次方案间局部控制无差异。
  • 颅底位置、肿瘤体积≥5 cc和复发疾病与更差局部控制相关。

核心结论

  • 颅内脑膜瘤经立体定向放射外科和放疗后长期随访观察到持久局部控制,三种分次方案局部控制结果相似,提示临床医生可根据临床因素调整放疗建议而不必担心疗效降低。

研究设计与样本

  • 回顾性综述纳入2008年1月至2021年12月间543例连续患者共613个组织学证实的世界卫生组织I级或影像学定义的良性颅内脑膜瘤病灶。
  • 治疗方式包括立体定向放射外科(中位剂量1250 cGy,n=211)、分次立体定向放射外科(2500 cGy分500 cGy分次,n=170)和常规分次立体定向放疗(中位剂量5022 cGy分≤200 cGy分次,n=232)。
  • 治疗设置包括根治性(n=475)或术后(n=138),术后治疗为次全切除后 upfront(n=43)或复发疾病(n=95)。

主要发现

  • 中位每病灶随访8.0年,所有病灶5/10/14年局部控制率为97.4%/86.8%/86.8%。
  • 颅底位置(P=0.01)、肿瘤体积≥5 cc(P=0.01)和复发疾病(P=0.02)与更差局部控制相关。
  • 按分次方案局部控制无差异;5/10年局部控制率立体定向放射外科为97.3%/85.7%,分次立体定向放射外科为97.5%/89.1%,常规分次立体定向放疗为97.5%/86.3%。
  • 立体定向放射外科剂量升级超过1250 cGy或常规分次立体定向放疗超过5040 cGy未改善局部控制。

关键数值与推荐

  • 立体定向放射外科中位剂量1250 cGy。
  • 分次立体定向放射外科2500 cGy分500 cGy分次。
  • 常规分次立体定向放疗中位剂量5022 cGy分≤200 cGy分次。

临床怎么用

  • 作者认为局部控制结果在三种分次方案间相似,提示临床医生可根据临床因素调整放疗建议而不必担心疗效降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgery (SRS) is an established treatment for intracranial meningioma, yet this approach is often precluded by tumor size or proximity to critical structures. Fractionated radiotherapy (RT) may be employed to address these limitations. We performed a comparison of local control (LC) outcomes between 3 stereotactic techniques. METHODS: A retrospective review was performed of 543 consecutive patients with 613 histologically-proven World Health Organization grade I or radiographically-defined benign intracranial meningioma treated with SRS (median dose: 1250 cGy) (n = 211), fractionated SRS (2500 cGy in 500 cGy fractions) (n = 170), or conventionally fractionated stereotactic radiotherapy (FSRT) (median dose: 5022 cGy in ≤200 cGy fractions) (n = 232) in the definitive (n = 475) or postoperative (n = 138) setting between January 2008 and December 2021. Postoperative treatment was delivered upfront after a subtotal resection (n = 43) or for recurrent disease (n = 95). RESULTS: Median follow-up per lesion was 8.0 years. LC for all lesions at 5/10/14 years was 97.4%/86.8%/86.8%. Base of skull location (P = 0.01), tumor volume ≥5 cc (P = 0.01), and recurrent disease (P = 0.02) were associated with inferior LC. No difference was observed in LC by fractionation regimen; LC at 5/10 years was 97.3%/85.7% for SRS, 97.5%/89.1% for fractionated SRS, and 97.5%/86.3% for FSRT. Dose escalation above 1250 cGy for SRS or above 5040 cGy for FSRT did not result in improved LC. CONCLUSIONS: Durable LC was observed at long-term follow-up of intracranial meningioma treated with stereotactic radiosurgery and RT. LC outcomes were similar across the 3 fractionation regimens, suggesting that clinicians may tailor RT recommendations based on clinical factors without concern for reduced efficacy.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Beighley A, Kesbeh Y, Rahimian J, et al. Impact of Fractionation Regimen on Local Control Following Frameless Linear Accelerator-Based Image-Guided Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma. World Neurosurg. 2024. PMID: 39069133. doi:10.1016/j.wneu.2024.07.148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。